AMRI Files New Patent Infringement Lawsuits against Dr. Reddy's Laboratories and Sandoz

• Press Release
• Source: Albany Molecular Research, Inc.
• On 8:00 am EDT, Tuesday September 15, 2009

ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI - News) announced today that it has filed two new patent infringement lawsuits in U.S. District Court in New Jersey against Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc. and Sandoz, Inc. (“the defendants”) for infringement of AMRI’s U.S. Patent Number 7,390,906. The recently issued patent relates to the manufacturing process for the active ingredient in sanofi-aventis’s Allegra^® and Allegra^®D drug products.

Related Quotes

Symbol	Price	Change
AMRI	8.69	+0.17

{"s" : "amri","k" : "c10,l10,p20,t10","o" : "","j" : ""}

This legal action relates to generic versions of sanofi-aventis’s Allegra^® and Allegra^®D drug products for which the defendants are seeking or have obtained marketing approval from the U.S. Food and Drug Administration (“FDA”) and which the defendants have marketed in the United States.

“We believe that this patent infringement filing strengthens our litigation strategy on Allegra^®, Allegra^®D-12, and Allegra^®D-24 against these generic drug companies in the United States and other jurisdictions. AMRI remains committed to vigorously protecting and enforcing its intellectual property,” said AMRI Chairman, President and CEO Thomas E. D'Ambra.

In November 2008, AMRI announced a settlement regarding two U.S. patent infringement litigations involving Allegra^® and Allegra^®D-12 to allow sanofi-aventis U.S. LLC to sublicense patents related to Allegra^® and Allegra^®D-12 to Teva Pharmaceuticals, USA, Inc. and Barr Laboratories, Inc. in the United States for which AMRI receives royalties on the sale of products containing fexofenadine hydrochloride (the generic name for the active ingredient in Allegra^® ) and products containing fexofenadine hydrochloride and pseudoephedrine hydrochloride (generic Allegra^®D-12) by Teva Pharmaceuticals, USA, Inc. and Barr Laboratories, Inc. through 2015, along with additional considerations.

About AMRI

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Forward-looking Statements

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission on March 13, 2009 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6049745

Media:
AMRI Corporate Communications
Andrea Schulz, 518-512-2226
or
Investors:
Peter Jerome, 518-512-2220
AMRI Director of Investor Relations